Our Network Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Tags: #Research #Clinical research #Oncology #Medical Oncology #AstraZeneca First global Phase III trial to show improved clinical outcome for systemic therapy in combination with transarterial chemoembolisation (TACE) in this setting.
